Trevor Allred
Stock Analyst at Oppenheimer
(4.57)
# 217
Out of 5,149 analysts
18
Total ratings
66.67%
Success rate
39.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $275 → $277 | $204.24 | +35.62% | 9 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $83 → $81 | $64.53 | +25.52% | 2 | Feb 25, 2026 | |
| LEGN Legend Biotech | Initiates: Outperform | $75 | $17.86 | +319.93% | 1 | Jan 7, 2026 | |
| DSGN Design Therapeutics | Initiates: Outperform | $18 | $10.00 | +80.00% | 1 | Jan 7, 2026 | |
| TBPH Theravance Biopharma | Initiates: Outperform | $27 | $13.96 | +93.41% | 1 | Dec 3, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $80 | $30.54 | +161.95% | 2 | Sep 23, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $85 | $131.51 | -35.37% | 1 | Sep 9, 2025 | |
| INVA Innoviva | Initiates: Outperform | $35 | $22.30 | +56.95% | 1 | Aug 11, 2025 |
Ligand Pharmaceuticals
Feb 27, 2026
Maintains: Outperform
Price Target: $275 → $277
Current: $204.24
Upside: +35.62%
BridgeBio Pharma
Feb 25, 2026
Maintains: Outperform
Price Target: $83 → $81
Current: $64.53
Upside: +25.52%
Legend Biotech
Jan 7, 2026
Initiates: Outperform
Price Target: $75
Current: $17.86
Upside: +319.93%
Design Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $18
Current: $10.00
Upside: +80.00%
Theravance Biopharma
Dec 3, 2025
Initiates: Outperform
Price Target: $27
Current: $13.96
Upside: +93.41%
MBX Biosciences
Sep 23, 2025
Maintains: Outperform
Price Target: $38 → $80
Current: $30.54
Upside: +161.95%
Palvella Therapeutics
Sep 9, 2025
Initiates: Outperform
Price Target: $85
Current: $131.51
Upside: -35.37%
Innoviva
Aug 11, 2025
Initiates: Outperform
Price Target: $35
Current: $22.30
Upside: +56.95%